Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping.
Read More…
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone011-41-22-716-9800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$29.13 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Quotient (NASDAQ:QTNT) Frequently Asked Questions
What is Quotient's stock symbol?
Quotient trades on the NASDAQ under the ticker symbol "QTNT."
How were Quotient's earnings last quarter?
Quotient Ltd (NASDAQ:QTNT) posted its quarterly earnings results on Monday, August, 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.03. The company had revenue of $8.17 million for the quarter, compared to the consensus estimate of $8.40 million. View Quotient's Earnings History.
When is Quotient's next earnings date?
What guidance has Quotient issued on next quarter's earnings?
Quotient issued an update on its second quarter 2020 earnings guidance on Monday, August, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $6.3-6.7 million, compared to the consensus revenue estimate of $6.5 million.
What price target have analysts set for QTNT?
1 brokers have issued 12 month price targets for Quotient's shares. Their forecasts range from $13.50 to $13.50. On average, they expect Quotient's stock price to reach $13.50 in the next year. This suggests a possible upside of 77.2% from the stock's current price. View Analyst Price Targets for Quotient.
What is the consensus analysts' recommendation for Quotient?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quotient.
Has Quotient been receiving favorable news coverage?
Media headlines about QTNT stock have trended somewhat positive on Tuesday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Quotient earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Quotient.
Are investors shorting Quotient?
Quotient saw a increase in short interest in September. As of September 30th, there was short interest totalling 4,560,000 shares, an increase of 40.3% from the August 30th total of 3,250,000 shares. Based on an average daily trading volume, of 322,700 shares, the days-to-cover ratio is currently 14.1 days. Approximately 8.0% of the shares of the company are short sold. View Quotient's Current Options Chain.
Who are some of Quotient's key competitors?
Some companies that are related to Quotient include Lantheus (LNTH), Heska (HSKA), Intellia Therapeutics (NTLA), Oxford Immunotec Global (OXFD), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Vermillion (VRML), ImmuCell (ICCC), Celldex Therapeutics (CLDX), GeneNews (GNWSF), Trinity Biotech (TRIB), Achieve Life Sciences (ACHV), Arca Biopharma (ABIO) and Akers Biosciences (AKER).
What other stocks do shareholders of Quotient own?
Who are Quotient's key executives?
Quotient's management team includes the folowing people:
- Mr. Franz Walt, CEO & Director (Age 60)
- Mr. Jeremy Stackawitz, Pres (Age 44)
- Mr. Edward Farrell, Pres (Age 49)
- Mr. Christopher J. Lindop, Chief Financial Officer (Age 61)
- Mr. John Allan, Corp. Sr. VP & CTO
How do I buy shares of Quotient?
Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Quotient's stock price today?
One share of QTNT stock can currently be purchased for approximately $7.62.
How big of a company is Quotient?
Quotient has a market capitalization of $504.98 million and generates $29.13 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. View Additional Information About Quotient.
What is Quotient's official website?
How can I contact Quotient?
Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800.
MarketBeat Community Rating for Quotient (NASDAQ QTNT)
MarketBeat's community ratings are surveys of what our community members think about Quotient and other stocks. Vote "Outperform" if you believe QTNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
